Sandisk Surges 32.7% After EPS Revision; ARGX, RCEL Rally
Sandisk (SNDK) jumped 32.7% from $1,224.78 to $1,625.78 after next-year EPS growth estimates hit 25.5%, amplified by JPMorgan's $2,250 price target and analyst comparisons to Micron. AVITA Medical (RCEL) climbed 29.6% on a 1.4pp EPS revision to 57.2% growth, supported by strong PermeaDerm trial results. Argenx (ARGX) gained 16.6% following positive Phase 3 ALKIVIA topline data in autoimmune myositis.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| SNDK | Technology | 2026-08-10 | N/A | +32.7% |
| RCEL | Healthcare | 2026-08-10 | +1.4pp | +29.6% |
| REED | Consumer Defensive | 2026-08-13 | +12.5pp | +27.2% |
| KURA | Healthcare | 2026-08-13 | N/A | +22.2% |
| ARGX | Healthcare | 2026-08-14 | N/A | +16.6% |
Why did SNDK stock jump in August 2026?
Sandisk (SNDK) jumped 32.7% from $1,224.78 to $1,625.78 after EPS next-year growth was revised to 25.5%, detected on Aug 10.
The gain accelerated on Aug 17 when JPMorgan restarted coverage with an Overweight rating and a $2,250 price target, while Citi set a $2,100 target. Momentum built on Sandisk's Aug 13 investor day, where management projected mid-to-high-teens revenue growth through 2030, ~80% gross margins, and a $93.9B customer backlog. Bank of America cited Sandisk's investor day as evidence for a more durable memory cycle, raising Micron's target to $1,550.
SNDK EPS revision history → · Screener snapshot from 2026-08-10 →
FAQ: SNDK
Why did Sandisk stock jump in August 2026?
Sandisk rose 32.7% to $1,625.78 from $1,224.78 after EPS next-year growth estimates climbed to 25.5% and JPMorgan initiated coverage with a $2,250 price target on Aug 17.
What is Sandisk's EPS growth estimate?
Sandisk's next-year EPS growth estimate stands at 25.5%, which triggered the screener on Aug 10 at $1,224.78.
Is SNDK a buy after the AI memory rally?
Analysts are bullish — JPMorgan has a $2,250 target and Citi a $2,100 target, though the stock trades at a premium on AI memory demand.
Why did RCEL stock jump in August 2026?
AVITA Medical (RCEL) jumped 29.6% from $7.60 to $9.85 after next-year EPS growth was revised from 55.9% to 57.2% on Aug 14.
The rally was reinforced by positive PermeaDerm-I Phase 3 results published Aug 18, showing a 70% cost advantage over cadaveric allograft at $148.70 vs $497.10 per %TBSA treated. The study met its primary endpoint with p<0.001, and PermeaDerm reduced preparation time by 95.7%. This positions AVITA's biosynthetic wound matrix as a compelling cost-saving alternative in burn care.
RCEL EPS revision history → · Screener snapshot from 2026-08-10 →
FAQ: RCEL
Why did RCEL stock jump recently?
AVITA Medical gained 29.6% to $9.85 from $7.60 after its EPS next-year growth estimate was revised up 1.4pp to 57.2%.
What caused AVITA Medical's surge?
The surge followed positive PermeaDerm-I trial results showing a 70% cost reduction versus allograft, announced Aug 18.
What is RCEL's EPS growth estimate?
RCEL's next-year EPS growth is 57.2%, up from 55.9% at the time of detection on Aug 10.
Why did REED stock jump in August 2026?
Reeds Inc (REED) climbed 27.2% from $0.92 to $1.17 after next-year EPS growth was revised sharply upward from 54.5% to 66.9%, a 12.5pp jump detected on Aug 13.
The move coincided with Q2 results showing gross margin tripling to 24% from 8% year-over-year and net loss narrowing 29% to $4.3 million, despite revenue falling 21% to $7.5 million. Management cited improved cost controls, lower inventory write-offs ($0.1M vs $1.6M), and a 30% reduction in delivery costs. Investors focused on the operational turnaround rather than the revenue decline.
REED EPS revision history → · Screener snapshot from 2026-08-13 →
FAQ: REED
Why did REED stock jump in August 2026?
REED rose 27.2% to $1.17 after its EPS next-year growth estimate jumped from 54.5% to 66.9%, a 12.5pp upward revision.
What is Reed's EPS growth estimate?
Reed's next-year EPS growth is now 66.9%, up substantially from 54.5% prior to the Aug 13 detection.
Is REED a buy after the turnaround?
The stock rallied on margin expansion to 24% from 8%, though revenue declined 21% to $7.5M — recovery is still early.
Why did KURA stock jump in August 2026?
Kura Oncology (KURA) gained 22.2% from $10.09 to $12.33 after its next-year EPS growth estimate held at 25.6%, detected on Aug 13.
The stock moved on Q2 earnings that beat Wall Street expectations — a loss of $0.77 per share vs. the $0.89 expected, with revenue of $20.9M topping the $16.9M forecast. KOMZIFTI generated $9.1M in net product revenue, up 57% sequentially, and captured majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market. A $7B total addressable market for frontline AML data supports long-term growth.
KURA EPS revision history → · Screener snapshot from 2026-08-13 →
FAQ: KURA
Why did KURA stock jump in August 2026?
Kura Oncology rose 22.2% to $12.33 after Q2 earnings beat estimates and EPS next-year growth was revised to 25.6%.
What caused Kura Oncology's surge?
KOMZIFTI revenue grew 57% sequentially to $9.1M, and the company beat both EPS and revenue expectations on Aug 12.
What is KURA's EPS growth estimate?
KURA's next-year EPS growth estimate is 25.6%, with the stock detected by the screener at $10.09 on Aug 13.
Why did ARGX stock jump in August 2026?
Argenx (ARGX) jumped 16.6% from $851.29 to $992.99 after next-year EPS growth was revised to 31.6%, detected on Aug 14.
The breakout was triggered by positive Phase 3 ALKIVIA topline results announced Aug 17, showing efgartigimod met its primary endpoint (p=0.0011) in autoimmune myositis. The study demonstrated rapid and sustained treatment benefit across both immune-mediated necrotizing myopathy and dermatomyositis, with consistent clinical impact in muscle and skin measures. This expands the addressable market for Vyvgart Hytrulo beyond myasthenia gravis into a new indication with no approved therapy for IMNM.
ARGX EPS revision history → · Screener snapshot from 2026-08-14 →
FAQ: ARGX
Why did ARGX stock jump recently?
Argenx rallied 16.6% to $992.99 after positive Phase 3 ALKIVIA trial results and an EPS next-year growth estimate of 31.6%.
What caused Argenx's surge?
The Phase 3 ALKIVIA study met its primary endpoint (p=0.0011) in autoimmune myositis, showing benefit across both IMNM and DM subtypes.
What is ARGX's EPS growth estimate?
ARGX's next-year EPS growth estimate is 31.6%, with the stock detected at $851.29 on Aug 14.
Today's performers signal that EPS revisions combined with hard catalysts — trial data, analyst upgrades, or margin improvements — create explosive moves. The market is rewarding companies with clear operational proof points, particularly in AI-driven memory and innovative biotech pipelines.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →